Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report

Toshiaki Takakura, MD; Hiroaki Kanemura, MD, MPH; Kazuko Sakai, PhD; Kazuto Nishio, MD, PhD; Kazuhiko Nakagawa, MD, PhD; Hidetoshi Hayashi, MD, PhD

JTO Clinical and Research Reports (Jun 2023)

Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report

Toshiaki Takakura, MD,
Hiroaki Kanemura, MD, MPH,
Kazuko Sakai, PhD,
Kazuto Nishio, MD, PhD,
Kazuhiko Nakagawa, MD, PhD,
Hidetoshi Hayashi, MD, PhD

Affiliations

Toshiaki Takakura, MD: Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan; Internal Medicine III, Wakayama Medical University, Wakayama, Japan
Hiroaki Kanemura, MD, MPH: Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan
Kazuko Sakai, PhD: Department of Genome Biology, Kindai University Faculty of Medicine, Osaka, Japan
Kazuto Nishio, MD, PhD: Department of Genome Biology, Kindai University Faculty of Medicine, Osaka, Japan
Kazuhiko Nakagawa, MD, PhD: Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan
Hidetoshi Hayashi, MD, PhD: Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan; Corresponding author. Address for correspondence: Hidetoshi Hayashi, MD, PhD, Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohno-higashi, Osaka-Sayama, Osaka 589-8511, Japan.

Journal volume & issue: Vol. 4, no. 6
p. 100523

Abstract

Read online

Resistance to ROS1 tyrosine kinase inhibitors is inevitable, but it has been unclear whether crizotinib might be effective after the development of entrectinib resistance. We here present a case of ROS1-rearranged NSCLC that responded to crizotinib after tumor progression due to MET polysomy during entrectinib treatment. This case suggests that crizotinib is an effective option for patients with MET polysomy, even after disease progression on entrectinib.

Published in JTO Clinical and Research Reports

ISSN: 2666-3643 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.journals.elsevier.com/jto-clinical-and-research-reports/

About the journal

Abstract

Keywords